A Phase 3 interventional study of Regorafenib (Stivarga, BAY73-4506) and Placebo in Metastatic Colorectal Cancer, sponsored by Bayer. Completed at 171 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-24.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing regorafenib in Colorectal Neoplasms — 10 open to participants now, 15 under way, 3 of them phase 3. regorafenib · Colorectal Neoplasms.
Among the 59 studies testing regorafenib in Colorectal Neoplasms, this one has the largest enrollment of the 58 interventional ones that give a count, is the only one that started in 2010, is one of 7 in phase 3, and was the 2nd registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →10 of the 59 studies testing regorafenib in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Chinese PLA General Hospital · Sites in China
Ages 18–75
National Cancer Institute, Naples · Sites in Italy
Ages 18+
The Methodist Hospital Research Institute · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Centre Hospitalier Universitaire de Besancon · Sites in France
Ages 18+
By country, each count listing its studies:
regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 39 · Phase 3 9 · Phase 4 3
First in 2009; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 760 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 55 across the 58 interventional studies. Of the 36 that completed or were terminated, 16 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 59 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
32 studies in Colorectal Neoplasms by Bayer: 2 open now, 2 under way, none of them phase 3. Of 29 finished, 6 (21%) have results posted.
Among the 32 studies in Colorectal Neoplasms by Bayer, this one has the largest enrollment of the 15 interventional ones that give a count, is the only one that started in 2010, is one of 4 in phase 3, and was the 4th registered.
Bayer’s Colorectal Neoplasms studies by the year they started, since 2008.
3 of the studies testing regorafenib in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06558773Chinese PLA General HospitalGSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC. | 2027-03-01 |
| NCT06425133Centre Hospitalier Universitaire de BesanconRegorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers | 2027-09 |
| NCT02955940Incyte CorporationAn Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 59 studies testing regorafenib in Colorectal Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 32 in Colorectal Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled multi-center phase III study to evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed on/after all approved drugs for CRC
All participants received Best Supportive Care. Acronyms used in Adverse events section: Gastrointestinal (GI), Genitourinary (GU), Not Otherwise Specified (NOS), Absolute Neutrophil Count (ANC), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Common Terminology Criteria for Adverse Events (CTCAE), International Normalized Ratio (INR), Central nervous system (CNS), Acute respiratory distress syndrome (ARDS), Cranial nerves (CN), Disseminated Intravascular Coagulation (DIC), Cardiac troponin T (cTnT).
Abbreviation used in Results section: Data Monitoring Committee (DMC). Adverse event collection will be covered in Adverse events section.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care(BSC).
Drug: Regorafenib (Stivarga, BAY73-4506) · Other: Best Supportive Care (BSC)
Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care (BSC).
Drug: Placebo · Other: Best Supportive Care (BSC)
160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
BSC includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
Overall Survival
Overall survival (OS) was defined as the time (days) from randomization to death due to any cause. Patients alive at the time of analysis were censored at the last date known to be alive. If a patient was lost to follow-up and there was no contact after randomization, this patient was censored at Day 1.
Time frame: From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis (IA).
Progression-free Survival (Based on Investigator's Assessment)
Progression-free survival was defined as the time (days) from date of randomization to date of first observed disease progression (radiological or clinical) or death due to any cause, if death occurred before progression was documented.
Time frame: From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.
Objective Tumor Response
The objective tumor response was defined as the percentage of patients with complete response (CR, tumor disappears) or partial response (PR, sum of lesion sizes decreased at least 30% from baseline) as best overall response. A best overall response was defined for all patients, using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1. Patients whose best overall response was not CR or PR, and any patients with no post-baseline assessments were considered nonresponders for the analysis.
Time frame: From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.
Disease Control
Disease control was defined as the percentage of patients whose best response was not PD \[sum of lesion sizes increased at least 20% from smallest sum on study or new lesions\] (ie, CR \[tumor disappears\], PR \[sum of lesion sizes decreased at least 30% from baseline\] or SD (stable disease)). SD included if at least 6 weeks after randomization.
Time frame: From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.
Tumor Response
A tumor response (best overall response) was defined for all patients, using the RECIST criteria, version 1.1. Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased at least 30% from baseline), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased at least 20% from smallest sum on study or new lesions). Clinical PD considered when radiographic imaging not possible.
Time frame: From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis. Tumor assessed at 8 week intervals.
| Milestone | Regorafenib (Stivarga, BAY73-4506)+BSC | Placebo+BSC |
|---|---|---|
| Started | 505 | 255 |
| Participants received treatment | 500 | 253 |
| Completed | 429 | 237 |
| Not completed | 76 | 18 |
| Withdrew: Adverse event | 50 | 7 |
| Withdrew: Withdrawal by subject | 17 | 5 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Did not receive study treatment | 5 | 2 |
| Withdrew: Switch to regorafenib | 0 | 4 |
| Milestone | Regorafenib (Stivarga, BAY73-4506)+BSC | Placebo+BSC |
|---|---|---|
| Started | 0 | 4 |
| Completed | 0 | 3 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
Overall survival (OS) was defined as the time (days) from randomization to death due to any cause. Patients alive at the time of analysis were censored at the last date known to be alive. If a patient was lost to follow-up and there was no contact after randomization, this patient was censored at Day 1.
| Days | Regorafenib (Stivarga, BAY73-4506)+BSC | Placebo+BSC |
|---|---|---|
| Overall Survival | 196 (178 to 222) | 151 (134 to 177) |
Progression-free survival was defined as the time (days) from date of randomization to date of first observed disease progression (radiological or clinical) or death due to any cause, if death occurred before progression was documented.
| Days | Regorafenib (Stivarga, BAY73-4506)+BSC | Placebo+BSC |
|---|---|---|
| Progression-free Survival (Based on Investigator's Assessment) | 59 (57 to 65) | 52 (51 to 53) |
The objective tumor response was defined as the percentage of patients with complete response (CR, tumor disappears) or partial response (PR, sum of lesion sizes decreased at least 30% from baseline) as best overall response. A best overall response was defined for all patients, using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1. Patients whose best overall response was not CR or PR, and any patients with no post-baseline assessments were considered nonresponders for the analysis.
| Percentage of participants | Regorafenib (Stivarga, BAY73-4506)+BSC | Placebo+BSC |
|---|---|---|
| Objective Tumor Response | 1.0 | 0.4 |
Disease control was defined as the percentage of patients whose best response was not PD \[sum of lesion sizes increased at least 20% from smallest sum on study or new lesions\] (ie, CR \[tumor disappears\], PR \[sum of lesion sizes decreased at least 30% from baseline\] or SD (stable disease)). SD included if at least 6 weeks after randomization.
| Percentage of participants | Regorafenib (Stivarga, BAY73-4506)+BSC | Placebo+BSC |
|---|---|---|
| Disease Control | 41.0 | 14.9 |
A tumor response (best overall response) was defined for all patients, using the RECIST criteria, version 1.1. Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased at least 30% from baseline), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased at least 20% from smallest sum on study or new lesions). Clinical PD considered when radiographic imaging not possible.
| Percentage of participants | Regorafenib (Stivarga, BAY73-4506)+BSC | Placebo+BSC |
|---|---|---|
| Complete Response (CR) | 0 | 0 |
| Partial Response (PR) | 1.0 | 0.4 |
| Stable Disease (SD) | 42.8 | 14.5 |
| Progressive Disease (PD) | 49.5 | 80.0 |
| Non CR/Non PD | 0.8 | 0.4 |
| Not applicable | 0.2 | 0 |
| Not assessed | 5.7 | 4.7 |
Collected over AE was collected up to 30 days after end of study treatment (per protocol) over a period of approximately 3.7 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Regorafenib (BAY73-4506)+BSC | — | 232/500 (46.4%) | 489/500 (97.8%) |
| Placebo+BSC | — | 103/253 (40.7%) | 229/253 (90.5%) |
| Placebo - Regorafenib After Unblinding | — | 2/4 (50%) | 4/4 (100%) |
| Event | Regorafenib (BAY73-4506)+BSC | Placebo+BSC | Placebo - Regorafenib After Unblinding |
|---|---|---|---|
| AscitesGastrointestinal disorders | 1/500 | 2/253 | 1/4 |
| VomitingGastrointestinal disorders | 3/500 | 0/253 | 1/4 |
| Death not associated with CTCAE term, Disease progression NOSGeneral disorders | 16/500 | 6/253 | 1/4 |
| Constitutional symptoms - OtherGeneral disorders | 34/500 | 23/253 | 0/4 |
| FeverGeneral disorders | 17/500 | 2/253 | 0/4 |
| Liver dysfunctionHepatobiliary disorders | 17/500 | 5/253 | 0/4 |
| Obstruction, GI, Small bowel NOSGastrointestinal disorders | 4/500 | 7/253 | 0/4 |
| Pain, Abdomen NOSGeneral disorders | 13/500 | 2/253 | 0/4 |
| Dyspnea (Shortness of breath)Respiratory, thoracic and mediastinal disorders | 12/500 | 4/253 | 0/4 |
| Obstruction, GI, ColonGastrointestinal disorders | 9/500 | 6/253 | 0/4 |
| Event | Regorafenib (BAY73-4506)+BSC | Placebo+BSC | Placebo - Regorafenib After Unblinding |
|---|---|---|---|
| FatigueGeneral disorders | 318/500 | 115/253 | 0/4 |
| DiarrheaGastrointestinal disorders | 218/500 | 44/253 | 2/4 |
| FeverGeneral disorders | 136/500 | 40/253 | 2/4 |
| Weight lossGeneral disorders | 167/500 | 30/253 | 2/4 |
| AnorexiaGastrointestinal disorders | 239/500 | 73/253 | 0/4 |
| Hand-foot skin reactionSkin and subcutaneous tissue disorders | 235/500 | 19/253 | 1/4 |
| Voice changesRespiratory, thoracic and mediastinal disorders | 160/500 | 16/253 | 1/4 |
| HypertensionCardiac disorders | 155/500 | 21/253 | 1/4 |
| Mucositis (functional/symptomatic), Oral cavityGastrointestinal disorders | 145/500 | 12/253 | 0/4 |
| Rash/DesquamationSkin and subcutaneous tissue disorders | 145/500 | 13/253 | 1/4 |
| Age, Continuous(Years) | Regorafenib (Stivarga, BAY73-4506)+BSC | Placebo+BSC | Total |
|---|---|---|---|
| Mean | 60.7 (22 to 82) | 60.1 (25 to 85) | 60.5 (22 to 85) |
| Sex: Female, Male(Participants) | Regorafenib (Stivarga, BAY73-4506)+BSC | Placebo+BSC | Total |
|---|---|---|---|
| Female | 194 | 102 | 296 |
| Male | 311 | 153 | 464 |
| Eastern Cooperative Oncology Group (ECOG) performance status (PS) before treatment(Participants) | Regorafenib (Stivarga, BAY73-4506)+BSC | Placebo+BSC | Total |
|---|---|---|---|
| 0 | 265 | 146 | 411 |
| 1 | 240 | 109 | 349 |
| KRAS mutation(Participants) | Regorafenib (Stivarga, BAY73-4506)+BSC | Placebo+BSC | Total |
|---|---|---|---|
| No | 205 | 94 | 299 |
| Yes | 273 | 157 | 430 |
| Unknown | 27 | 4 | 31 |
Showing the first 100 of 171 sites across 19 countries. Choose a country and city above to see the rest.
The record gives a start of Apr 2010, a primary completion of Jul 2011 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Regorafenib